Mind & sleep

NA Semax Amidate

Terminally modified Semax analogue

Community reportsFocus · memory2

No FDA-approved product identified for this exact research entry in the targeted review.

What does it do?

Modified Semax derivative marketed for cognition. Evidence for standard Semax does not prove this derivative's efficacy, extended half-life or superior delivery.

Approved & studied uses

No established medical use is documented for this formulation.

Community uses Reported, unvalidated

Focus, learning and memory

7

Source reports attention, fatigue resistance and consolidation; direct clinical evidence limited.

Neuroprotection and stroke recovery

7

Parent-compound/experimental extrapolation, not an established derivative indication.

Delivery research

7

Nasal/injectable exposure claims require measured PK.

Reasons people report using it; these do not establish benefit.7

Evidence limits

View research →

No controlled human trial of this exact modified analogue was verified.1

1 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Key safety information

All risks →

Evidence limitation

Comparative human potency and exposure are unknown.1

No FDA-approved product identified for this exact research entry in the targeted review.

Molecular information

Amino-acid sequence

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

Residue count only · sequence not verified27

An exact sequence has not been verified for this formulation.

Reference identity · not independently confirmed7

Length7 amino acids
Molecular weight · Da1,007.16 Da
Formula, sequence notation & identity
Molecular formulaNot independently verified27

Terminally modified Semax analogue

The exact formulation, clinical benefits and long-term safety require further verification.

Pep-Pedia identity details

7 amino acids · 1,007.16 Da

Asn-Ala-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂

Reference description; checked chemical identity above takes precedence when available.7

Pharmacokinetics

How long does it stay in the body?

Reported half-lifeHuman half-life not verified2

No numerical human elimination estimate was verified for the exact material in this review.

No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.

What to expect

Study outcomes

Exact analogue has an evidence gap

No controlled human trial of this exact modified analogue was verified.1

Reported timelines

Reference & community

Nasal: 15–30 min onset, 1–2h peak, 2–12h taper

Source-reported, unvalidated derivative timeline.7

Injection: 30–60 min onset, 2–4h peak

No established clinical response schedule.7

These are reported timelines, not a prediction of your response.

Community poll 10 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Primary goal

Cognitive enhancement94%
General wellness3%
Other: PMDD luteal phase suppose2%
Other: Cognitive function 2%

Number of responses to this question: not disclosed.

Source & limitations

The source displays “661 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.

  • Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
  • The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
  • Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
  • Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
  • This is a dated snapshot, not a live survey or current recommendation.
Protocols

Doses & schedules

Compare purpose, amount, route, frequency, and duration.

Source corrections

Source's 'proven efficacy' and superior bioavailability language overstates verified derivative-specific evidence. Interaction labels are hypotheses.

6 rows
Route

Scroll to compare all columns →

One row for each documented route and dose or dose range
RouteDoseFrequencyGoal / evidenceDurationReferences
IntranasalNasal spray600μg1x dailyCognitive enhancementReference report10-30 days7
IntranasalNasal spray800μg1x dailyMental fatigue resistanceReference report10-30 days7
IntranasalNasal spray600μg2x dailyMemory enhancementReference report10-30 days7
IntranasalNasal spray1200μg1x dailyNeuroprotectionReference report10-30 days7
SubQ200μg1x dailyResearch protocolReference report7-21 days7
SubQ400μg1x dailyNeuroprotection studyReference report7-21 days7

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports7

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Nasal

Use period
10-30 days
Break
Equal length break
Reported timing

Morning or early afternoon

Injectable

Use period
7-21 days
Break
Equal break
Reported timing

Morning preferred

Side effects & safety

Evidence limitation

Comparative human potency and exposure are unknown.

1

Evidence limitation

Parent Semax tolerability cannot be assumed to cover this modified compound.

1

Additional reported cautions

Reference reports7

Local/systemic effects

Nasal irritation/bleeding, headache, insomnia, allergy or injection infection; pregnancy safety unknown.

Quality and route

Congestion changes absorption; sterile preparation does not establish efficacy/safety.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

7 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

Modafinil

Caution reported

Possible overstimulation.7

Reference report · Pep-Pedia label: Monitor Combination

Blood-pressure medicines

Caution reported

Possible vascular effects.7

Reference report · Evidence context: Monitor combination

MAO inhibitors

Avoidance reported

Uncharacterized neurotransmitter interaction.7

Reference report · Pep-Pedia label: Avoid Combination

NA Selank amidate

Unverified pairing

Untested cognitive/anxiety pairing.7

Reference report · Pep-Pedia label: Synergistic

BPC-157

Unverified pairing

Safety unestablished.7

Reference report · Pep-Pedia label: Compatible

Lion's mane

Unverified pairing

Neurotrophic hypothesis.7

Reference report · Pep-Pedia label: Compatible

Other medicines or peptides

Not established

No exact-product human interaction study was verified; lack of evidence is not evidence of safety.2

Research context

Reconstitution

No validated preparation identified

No product-specific preparation or stability instruction was verified. A dilution calculation does not establish suitability for injection.2

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Nasal

Pep-Pedia distinguishes preservative-free saline from BAC water for nasal preparations.

Solvents mentioned
Sterile saline / Bacteriostatic water — source alternative
Reported parameters
Source-reported intervals: saline, 24–48 hours; BAC water, 28 days; both refrigerated. · It warns that benzyl alcohol in BAC water may irritate nasal tissue.

The source also suggests frozen aliquots; it does not establish validated stability or container compatibility for every nasal formulation.

Injectable

The injectable steps name BAC water and refrigeration.

Solvents mentioned
Bacteriostatic water
Reported parameters
Reported interval: 28 days.
7
Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearanceWhite, fluffy powderReported appearanceClear solutionReported concernDiscolored powder
7

Available forms

No verified packaging examples included.

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Refrigerated lifetime not established

The checked sources do not establish how long this research preparation remains stable and sterile after mixing.7

Full storage notes from Pep-Pedia7
Nasal

Refrigerate 2-8°C

Injectable

Refrigerate

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Research findings

No human data verified

Source context

Source's 'proven efficacy' and superior bioavailability language overstates verified derivative-specific evidence. Interaction labels are hypotheses.

Compound identity & other names

NA Semax Amidate is marketed as N-acetyl Semax with a C-terminal amide. Parent Semax findings do not establish this exact analogue’s effects or improved delivery.

No FDA-approved product identified for this exact research entry in the targeted review.

How it may work

Proposed neurotrophic/neurotransmitter pathways; direct nasal brain access and systemic bioavailability require derivative-specific confirmation.7

Exact analogue has an evidence gap

Parent-Semax experiments do not establish that acetylation and amidation preserve benefit, improve brain exposure, or make a safe human product.

1
Research areas and evidence gaps
  • No controlled human trial of this exact modified analogue was verified.
  • A product-specific research-vial quantity was not independently verified in this review.
Community reports Unvalidated

Pep-Pedia discusses cognition and mental fatigue interest.2

Editorial summary, not a measured community survey, clinical protocol or recommendation.

Search coverage and review status

No exact-analogue controlled human trial was verified. Recent parent-Semax cell research is labeled as indirect.

Checked
2026-10-12
Search
"N-acetyl" "Semax" "2025" study
Catalog
Pep-Pedia ↗ · 4 listed references retained
  • Targeted search and selected primary-source checks, not an exhaustive systematic review.
  • Preserved bibliography entries marked unreviewed have not had their findings independently verified.

AI-prepared summaries. Independent medical editorial review is pending.

References

Original sources and review status. Open a reference to read its summary.

7 sources

1The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain NeuronsPreclinical · 2025 · pubmed.ncbi.nlm.nih.govAbstract checked
AI-PREPARED SUMMARY

This study used parent Semax in rat brain slices, not N-acetyl Semax amidate. Calcium-signaling observations cannot establish the modified analogue’s effects.

Exact analogue has an evidence gap

Parent-Semax experiments do not establish that acetylation and amidation preserve benefit, improve brain exposure, or make a safe human product.

Additional research · Checked 2026-10-12

Original source
2Pep-Pedia: NA Semax AmidateCommunity · Accessed 2026 · pep-pedia.orgCommunity source checked
AI-PREPARED SUMMARY

Secondary editorial profile and reported practices; not clinical validation.

Original source
3Default Mode Network Enhancement (2018)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: The reported imaging changes concern parent Semax, not the amidated derivative; an fMRI change alone does not establish better memory.

Reported population / model
24 participants

Reported study details
1% solution intranasal · fMRI monitoring · DMN volume increase

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
4Stroke Recovery and BDNF Enhancement (2018)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: Parent Semax studies reportedly linked higher BDNF with motor recovery after stroke; the modified NA-Semax product was not directly tested.

Reported population / model
110 stroke patients

Reported study details
10-day treatment protocol · BDNF level monitoring · Motor function improvement

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
5Gene Expression and Neuroprotection (2014)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: Parent Semax altered immune, vascular and injury-response gene expression in rat brain-ischemia models; amidated-product efficacy was not tested.

Reported population / model
Rat model

Reported study details
Genome-wide analysis · 3-24 hour timepoints · 96+ gene expression changes

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
6Cognitive Enhancement in Fatigued Subjects (1996)No study link suppliedReference · Accessed 2026 · pep-pedia.orgPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY

Pep-Pedia reports: The source reports memory accuracy of 71% versus 41% during demanding work conditions with Semax; this is not direct NA-Semax-amidate evidence.

Reported population / model
Human study

Reported study details
250-1000μg intranasal · 24-hour effects · 71% vs 41% memory accuracy

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report
7Pep-Pedia: NA Semax Amidate — route-specific referenceReference page checked; underlying claims require separate verification.Community · Checked 2026 · pep-pedia.orgCommunity source checked
AI-PREPARED SUMMARY

Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.

Content coverage audit · Checked 2026-10-12

Original source
Source details